Table 1 Baseline clinicopathological characteristics of all enrolled patients
Characteristics | Total | AR-V7 positive | AR-V7 negative | P |
|---|---|---|---|---|
No. of patients (%) | 110 | 21 | 89 | Â |
Age (mean, SD, year) | 66.02 (6.12) | 65.38 (5.35) | 66.17 (6.31) | 0.598 |
Gleason score (n, %) | ||||
  ≤ 7 | 77 (65.25) | 14 (66.67) | 56 (62.92) | 0.748 |
  ≥ 8 | 41 (34.75) | 7 (33.33) | 33 (37.08) | |
Pathological T stage (n, %) | ||||
 2 | 75 (63.56) | 14 (66.67) | 51 (57.30) | 0.555 |
 3 | 33 (27.97) | 5 (23.81) | 32 (35.96) | |
 4 | 10 (8.47) | 2 (9.52) | 6 (6.74) | |
Pathological N stage (n, %) | ||||
 0 | 83 (70.34) | 17 (80.95) | 62 (69.66) | 0.444 |
 1 | 35 (29.66) | 4 (19.05) | 27 (30.34) |  |
Surgical Margin (n, %) | ||||
 R0 | 99 (83.90) | 17 (80.95) | 74 (83.15) | 0.811 |
 R1 | 19 (16.10) | 4 (19.05) | 15 (16.85) | |
Preoperative TPSA (mean, SD, ng/ml) | 44.46 (58.80) | 58.32.44 (81.76) | 41.19 (52.02) | 0.368 |
Prostate volume (mean, SD, cm3) | 71.74 (34.02) | 60.90 (18.15) | 74.30 (36.39) | 0.105 |
PSAD (mean, SD, ng/ml/cm3) | 0.73 (1.17) | 1.29 (2.29) | 0.60 (0.63) | 0.186 |
Follow-up time (mean, SD, months) | 57.57 (10.56) | 57.67 (9.24) | 57.55 (10.90) | 0.964 |